<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10584883</article-id><article-id pub-id-type="pmc">2374330</article-id><article-id pub-id-type="pii">6690830</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690830</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: long-term results of a phase II trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Eberhardt</surname><given-names>W</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Stamatis</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Stuschke</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Wilke</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>M&#x000fc;ller</surname><given-names>M R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kolks</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Flasshove</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sch&#x000fc;tte</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Stahl</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Schlenger</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Budach</surname><given-names>V</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Greschuchna</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>St&#x000fc;ben</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Teschler</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Sack</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Seeber</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Departments of Internal Medicine (Cancer Research) and,<label>2</label>Radiotherapy, West German Cancer Center, University of Essen Medical School, Hufelandstra&#x000df;e 55, 45122 Essen, Germany</aff><aff id="aff3"><label>3</label>Department of Pneumology and Thoracic Surgery, Ruhrlandklinik, Essen-Heidhausen, Germany</aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:Wilfried.eberhardt@uni-essen.de">Wilfried.eberhardt@uni-essen.de</email></corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>1999</year></pub-date><volume>81</volume><issue>7</issue><fpage>1206</fpage><lpage>1212</lpage><history><date date-type="received"><day>02</day><month>11</month><year>1998</year></date><date date-type="rev-recd"><day>28</day><month>04</month><year>1999</year></date><date date-type="accepted"><day>07</day><month>06</month><year>1999</year></date></history><copyright-statement>Copyright 1999, Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Following mediastinoscopy, a prognostically orientated multimodality approach was chosen in selected small-cell lung cancer (SCLC) patients with hyperfractionated accelerated chemoradiotherapy (Hf-RTx) and definitive surgery (S). Stage IB/IIA patients had four cycles of cisplatin/etoposide (PE) and surgery. Stage IIB/IIIA patients had three cycles PE followed by one cycle concurrent chemoradiation including Hf-RTx and surgery. Most stage IIIB patients were not planned for surgery and had CTx followed by sequential RTx or one cycle concurrent CTx/RTx. Of 46 consecutive patients (stage IB six, IIA two, IIB/IIIA 22, IIIB 16) 43 (94&#x00025;) showed an objective response. Twenty-three of patients (72&#x00025;) planned for inclusion of S were completely resected (R0) (IB 6/6, IIA 2/2, IIB/IIIA 13/22, IIIB 2/2). Overall toxicity was acceptable &#x02013; one patient died of septicaemia, no perioperative deaths occurred. Median follow-up of patients alive (<italic>n</italic> = 21) is 52 months (30+ &#x02013; 75+). Median survival and 5-year survival rate of all patients are 36 months and 46&#x00025;, in R0 patients 68 months and 63&#x00025; (R0-IIB/IIIA/IIIB: not yet reached and 67&#x00025;). This multimodality treatment including surgery proved highly effective with 100&#x00025; local control and remarkable long-term survival after complete resection, even in locally advanced SCLC stages IIB/IIIA patients. &#x000a9; 1999 Cancer Research Campaign</p></abstract><kwd-group><kwd>small-cell lung cancer</kwd><kwd>combined modality</kwd><kwd>surgery</kwd><kwd>neoadjuvant</kwd></kwd-group></article-meta></front></article>


